Related Experiment Video
Updated: Jul 4, 2025
In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research
Published on: September 16, 2019
Localization of Sites of Osimertinib Action in Rat Intestine, Skin, and Lung by Immunohistochemistry
Yuta Yamamoto1, Tetsuya Saita2, Hiroto Kataoka2
1Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga 849‑8501, Japan.
Abstract:
Osimertinib is a third-generation, irreversible tyrosine kinase inhibitor (TKI) of epidermal growth factor receptor (EGFR) that selectively inhibits both EGFR-TKI-sensitizing and EGFR T790M resistance mutations and has shown efficacy in patients with non-small-cell lung cancer. In this study, we created osimertinib-specific antibodies and developed an immunohistochemistry (IHC) for locating the sites of osimertinib action. Moreover, we located osimertinib-protein conjugates in intestinal, dermal, and lung tissues of rats, thereby using our IHC to visualize the sites of the adverse effects of osimertinib, including diarrhea, skin disorder, and interstitial pneumonia. This report is the first to elucidate the localization of the sites of action of osimertinib in the rat intestine, skin, and lung and is expected to help clarify the mechanism of osimertinib-induced adverse effects.
Insights
This study developed an immunohistochemistry method to locate where osimertinib acts in the body. This technique visualized osimertinib-protein conjugates in rat tissues, helping to understand adverse effects like diarrhea and lung issues.
Area of Science:
- Pharmacology
- Oncology
- Biochemistry
Background:
- Osimertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) effective against non-small-cell lung cancer, including resistance mutations.
- Understanding the precise sites of drug action is crucial for elucidating mechanisms of efficacy and adverse effects.
Purpose of the Study:
- To develop and validate an immunohistochemistry (IHC) method for visualizing osimertinib localization within tissues.
- To identify the specific tissue sites where osimertinib interacts with proteins in a preclinical model.
- To correlate osimertinib localization with observed adverse effects.
Main Methods:
- Generation of osimertinib-specific antibodies.
- Development of an IHC assay for detecting osimertinib-protein conjugates.
- Application of IHC to analyze intestinal, dermal, and lung tissues from rats treated with osimertinib.
Main Results:
- Successful development of an IHC method to detect osimertinib-protein conjugates.
- Localization of osimertinib-protein conjugates in rat intestinal, dermal, and lung tissues.
- Visualization of drug action sites potentially linked to adverse effects such as diarrhea, skin disorders, and interstitial pneumonia.
Conclusions:
- The developed IHC method effectively visualizes osimertinib localization in preclinical tissues.
- This approach provides insights into the tissue-specific sites of osimertinib action.
- The findings are expected to aid in clarifying the mechanisms underlying osimertinib-induced adverse effects.
